Research advances in the treatment of type 2 diabetes mellitus.
Caro
J
J
Eli Lilly and Company, Indianapolis, USA.
Wishner
K L
KL
D002626:Chemistry, Pharmaceutical; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics; D005934:Glucagon / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use; D007328:Insulin / Q000737:chemistry / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011498:Protein Precursors / Q000627:therapeutic use; D012106:Research; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D013844:Thiazoles; D045162:Thiazolidinediones; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; C089946:2,4-thiazolidinedione; D011493:Protein Kinase C